CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 328 enrolled
Drug / intervention
Rasagiline +1 moredrug
Likely dose
Rasagiline 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01049984
NCT01049984Phase 4Completed
CompareCT.gov

A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease

Teva Neuroscience, Inc.·interventional·Posted Jan 15, 2010·Updated May 20, 2016

In Brief

A Phase 4 clinical trial evaluating Rasagiline and Placebo for Parkinson's Disease. Completed, enrolled 328 participants across 58 sites.

Detailed Summary

To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
CollaboratorsH. Lundbeck A/S

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 15, 2010
Enrollment StartDec 1, 2009
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.5 years ago

Interventions

Rasagilinedrug

1mg tablet daily for 18 weeks

Placebodrug

one tablet daily for 18 weeks